Certolizumab pegol biosimilar (Xbrane Biopharma)

N/A

Report date: 2025/07/14 15:18:32

Base Information

Drug NameCertolizumab pegol biosimilar (Xbrane Biopharma)
Drug Alias NameXcimzaneBIIB801BIIB-801XB003XB-003 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXbrane Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesXbrane Biopharma AbBiogen IncAlvotech hf
Inactive CompaniesN/A
Active IndicationsPsoriasisCrohn DiseaseArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A